- Home
- ANVS vs VNRX Comparison
ANVS vs VNRX Comparison
Compare ANVS & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | VNRX |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.3M | 38.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANVS | VNRX |
|---|---|---|
| Price | $4.31 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $13.50 | $3.17 |
| AVG Volume (30 Days) | ★ 3.9M | 2.6M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | N/A | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $1.11 | $0.27 |
| 52 Week High | $6.37 | $0.94 |
Technical Indicators
Market Signals| Indicator | ANVS | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 34.01 |
| Support Level | $4.01 | $0.28 |
| Resistance Level | $4.82 | $0.34 |
| Average True Range (ATR) | 0.58 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 54.37 | 21.61 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.